Royalty Historical Income Statement
| RPRX Stock | USD 26.66 0.06 0.23% |
Historical analysis of Royalty Pharma income statement accounts such as Selling General Administrative of 262.2 M, Gross Profit of 1.4 B, Operating Income of 1.1 B or Net Income From Continuing Ops of 1.1 B can show how well Royalty Pharma Plc performed in making a profits. Evaluating Royalty Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Royalty Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Royalty Pharma Plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Royalty Pharma Plc is a good buy for the upcoming year.
Royalty |
About Royalty Income Statement Analysis
Royalty Pharma Plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Royalty Pharma shareholders. The income statement also shows Royalty investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Royalty Pharma Income Statement Chart
Add Fundamental
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Royalty Pharma Plc minus its cost of goods sold. It is profit before Royalty Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Royalty Pharma Plc. It is also known as Royalty Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Royalty Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Royalty Pharma Plc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Royalty Pharma's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 2.5 B in 2024, whereas Gross Profit is likely to drop slightly above 1.4 B in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 23.0M | 5.7M | 395.1M | 414.9M | Interest Income | 53.5M | 78.3M | 72.3M | 45.0M |
Royalty Pharma income statement Correlations
Click cells to compare fundamentals
Royalty Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Royalty Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 268.6M | 157M | 166.1M | 188.0M | 187.2M | 196.5M | |
| Total Revenue | 1.8B | 2.1B | 2.3B | 2.2B | 2.4B | 2.5B | |
| Research Development | 83.0M | 26M | 200.1M | 177.1M | 52M | 57.5M | |
| Cost Of Revenue | 1.0B | 88.1M | 23.0M | 5.7M | 560.7M | 588.7M | |
| Selling General Administrative | 103.4M | 182M | 182.8M | 227.3M | 249.7M | 262.2M | |
| Gross Profit | 794.9M | 2.0B | 2.3B | 2.2B | 1.8B | 1.4B | |
| Operating Income | 2.6B | 1.6B | 1.4B | 977.5M | 1.5B | 1.1B | |
| Net Income From Continuing Ops | 2.5B | 1.7B | 1.2B | 230.1M | 1.7B | 1.1B | |
| Ebit | 2.6B | 1.7B | 1.4B | 922.9M | 1.5B | 1.2B | |
| Total Operating Expenses | (808.9M) | 527M | 858.7M | 1.3B | 862.4M | 905.5M | |
| Income Before Tax | 2.5B | 1.7B | 1.2B | 230.1M | 1.7B | 1.1B | |
| Total Other Income Expense Net | (161.8M) | 106.6M | (189.5M) | (77.0M) | 207.9M | 218.3M | |
| Net Income Applicable To Common Shares | 2.3B | 975.0M | 619.7M | 42.8M | 49.3M | 46.8M | |
| Net Income | 2.3B | 495.2M | 478.8M | 42.8M | 1.1B | 771.0M | |
| Income Tax Expense | 349.3M | 1.1B | 762.4M | 187.2M | 565.3M | 438.6M | |
| Net Interest Income | (246.2M) | (157M) | (112.6M) | (109.6M) | (114.9M) | (120.6M) | |
| Interest Income | 22.3M | 28.4M | 53.5M | 78.3M | 72.3M | 45.0M | |
| Depreciation And Amortization | 14.1M | 23.1M | 23.0M | 5.7M | 395.1M | 414.9M | |
| Other Operating Expenses | 808.9M | 527M | 858.7M | 1.3B | 862.4M | 858.0M | |
| Ebitda | 2.6B | 1.7B | 1.5B | 928.6M | 1.9B | 1.8B | |
| Minority Interest | 35.9M | 726.9M | 621.5M | 187.2M | (565.3M) | (537.0M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.